Previous 10 | Next 10 |
home / stock / bmymp / bmymp news
Since the acquisition of Alexion was completed, we were watching AstraZeneca from the sidelines. Holding but not taking any further action. Q4/FY 2021 earnings are marking a turning point for the company, for its future, for its dividend, and (consequently) for us. This has been nothi...
Biotechs struggled in 2021 as indexes lagged the broader market. So far in 2022, biotechs have dropped sharply as interest rate uncertainty has created a risk-off market. A rising interest rate environment remains the biggest risk for biotechs. With the S&P 500 biotech index h...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
SDOG is a dividend ETF with an equal-weight methodology. Its valuation is attractive. It is quite risky regarding quality and volatility metrics. For further details see: SDOG: High Yield, Good Value, Questionable Quality
Bristol-Myers Squibb Co (BMY) Q4 2021 Earnings Conference Call February 04, 2022, 08:00 ET Company Participants Timothy Power - VP & Head, IR Giovanni Caforio - Chairman & CEO David Elkins - EVP & CFO Christopher Boerner - EVP & Chief Commercialization Officer Samit Hirawat - ...
This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to obtain quality scores, sort them in descending order, and break ties with additional metrics. ...
Expert prediction results. My predictions’ current status. Unfinished business for 2022. For further details see: 2021 Prediction Roundup
Sutro Biopharma expects to report interim results from a phase 1 study using STRO-002 at KOL event on Wednesday Jan. 5, 2022, at 5 p.m. ET. Antibody Drug Conjugate STRO-002 is being developed for the treatment of patients with ovarian cancer and endometrial cancer. STRO-001 is ano...
The time has come for our yearly market outlook article. Most of what we planned for 2021 has happened, how will we do in 2022? I discuss inflation, the fed, value vs. growth and more. For further details see: 2022 Market Outlook For Dividend Investors
This weekly article series provides a summary of dividend changes. A summary table presents relevant data and key statistics of dividend increases. We highlight one of the stocks and present performance, valuation, and earnings charts. For further details see: Dividend I...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb $2Pr Company Name:
BMYMP Stock Symbol:
OTCMKTS Market:
Bristol-Myers Squibb $2Pr Website: